Nuclear factor erythroid 2-related factor 2 (NRF2) inhibition stands out as a potential strategy to elevate the labile iron pool (LIP), intensifying ferroptotic sensitivity in cancer cells that is clinically relevant to ovarian cancer [38]. The gene discussed is NFE2L2; the disease is ovarian cancer.